10th antibody industrial symposium: new developments in antibody and adoptive cell therapies.

Autor: Antunes A; MabDesign, Lyon, France., Alvarez-Vallina L; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; H120-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Centre (CNIO), Madrid, Spain., Bertoglio F; Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Department of Biotechnology, Braunschweig, Germany, Current address., Bouquin N; REGIMBEAU, Paris - 69006 Lyon, France., Cornen S; Innate Pharma, Marseille, France., Duffieux F; Large Molecules Research, Sanofi, Vitry-Sur-Seine, France., Ferré P; Compugen Ltd, Holon, Israel., Gillet R; REGIMBEAU, Paris - 69006 Lyon, France., Jorgensen C; IRMB, université de Montpellier, Inserm U1183, Montpellier, France.; Unité d'immunologie clinique et de thérapeutique des maladies ostéoarticulaires, département de rhumatologie, hôpital Lapeyronie, Montpellier, France., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA., Maillère B; Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France., Negre H; Institut de Recherches Internationales Servier, Suresnes, France., Pelegrin M; IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France., Poirier N; OSE Immunotherapeutics, Nantes, France., Reusch D; Pharma Technical Development Analytics Biologics, Roche Diagnostics GmbH, Penzberg, Germany., Robert B; IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France., Serre G; Institut Toulousain des maladies infectieuses et inflammatoires - INFINITY- Inserm, CNRS, Université Toulouse III, Toulouse, France., Vicari A; Calypso Biotech SA, Plan-les-Ouates, Switzerland., Villalba M; IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France., Volpers C; Michalski Huettermann & Partner, Frankfurt/Main, Germany., Vuddamalay G; MabDesign, Lyon, France., Watier H; CEPR, INSERM U1100 Université de Tours, et CHU de Tours, Tours cedex, France., Wurch T; Evotec, Toulouse, France., Zabeau L; Orionis Biosciences BV, Ghent, Belgium., Zielonka S; Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany., Zhang B; Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA., Beck A; Biologics CMC & Developability, Institut de Recherche Pierre Fabre, St Julien-en-Genevois Cedex, France., Martineau P; IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France.

Publikováno v: MAbs [MAbs] 2023 Jan-Dec; Vol. 15 (1), pp. 2211692.

Hunting the Cell Cycle Snark.

Autor: Norris, Vic¹ (AUTHOR) victor.norris@univ-rouen.fr

Publikováno v: Life (2075-1729). Oct2024, Vol. 14 Issue 10, p1213. 24p.

Resistance to trifluoroperazine, a calmodulin inhibitor, maps to the fabD locus in Escherichia coli

Autor: Tempête M, S. J. Séror, Bouquin N, I. B. Holland

Publikováno v: Moleculargeneral genetics : MGG. 246(5)

A mutant, tfpA1, resistant to the calmodulin inhibitor trifluoroperazine (TFP) at 30 degrees C, was isolated in Escherichia coli. The mutant showed a reduced growth rate at 30 degrees C and was temperature sensitive (ts) at 42 degrees C for growth, f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4cc4ed1fb8605926f1b45cde801f04
https://pubmed.ncbi.nlm.nih.gov/7700236

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.